Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Blood (2024) 144 (Supplement 1): 997.

https://doi.org/10.1182/blood-2024-201729

Published: 2024

Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2024-203274

Published: 2024

Journal Articles

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Blood (2024) 144 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2024-208186

Published: 2024

Journal Articles

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Claire N Harrison, David M. Ross, Lynette C.Y. Chee, Shuhying Tan, Marielle Wondergem, Timothy Devos, Christine Graham, Allie McGinty, Michael Pace, Hongying Wang, Ying Jiang, Suresh Bobba, Katie Louise Dawson, Christopher Rovaldi, Montagu Hankin, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2023-187099

Published: 2023

Journal Articles

TBI/Ratg-Based Conditioning for Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in 11 Cases of Chemotherapy-Resistant Advanced-Stage Peripheral T-Cell Lymphoma

JUN Zhu, Rong Xu, Chun Wang, Chuxian Zhao, Ying Jiang, Daolin Wei, Shan Shao, Huixia Liu, Su Li

Blood (2023) 142 (Supplement 1): 6981.

https://doi.org/10.1182/blood-2023-174062

Published: 2023

Journal Articles

Real-World Effectiveness and Safety of Hetrombopag for Delayed Platelet Engraftment Post-Allogeneic Hematopoietic Stem Cell Transplantation

JUN Zhu, Yun Lou, Chuxian Zhao, Ying Jiang, Daolin Wei, Chun Wang, Shan Shao, Huixia Liu, Su Li

Blood (2023) 142 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2023-178605

Published: 2023

Journal Articles

Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Shan Shao, Huixia Liu, Ying Jiang, Su Li, Daolin Wei, JUN Zhu, Chun Wang, Chuxian Zhao

Blood (2023) 142 (Supplement 1): 7007.

https://doi.org/10.1182/blood-2023-173673

Published: 2023

Journal Articles

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Lynette C.Y. Chee, David M. Ross, Thomas Cluzeau, Shuhying Tan, Aristoteles Giagounidis, David Valcarcel, Montserrat Arnan, Maria Diez-Campelo, Christine Graham, Allie McGinty, Miranda Ross, Suresh Bobba, Wei Feng, Ying Jiang, Montagu Hankin, Christopher Rovaldi, Simon Cooper, Dena Grayson, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 1089.

https://doi.org/10.1182/blood-2023-186326

Published: 2023

Journal Articles

Impact of Immunosuppression Intensified Conditioning Regimen for Patients with Strong Positive Pre-Transplantation Donor Specific Anti-HLA Antibodies (DSAs) Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Huixia Liu, Daolin Wei, Shan Shao, Ying Jiang, Su Li, JUN Zhu, Chun Wang, Chuxian Zhao

Blood (2023) 142 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2023-174240

Published: 2023

Journal Articles

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Maria Diez-Campelo, David M. Ross, Aristoteles Giagounidis, Shuhying Tan, Thomas Cluzeau, Lynette C.Y. Chee, David Valcarcel, Montserrat Arnan, Christine Graham, Allie McGinty, Miranda Ross, Wei Feng, Ying Jiang, Suresh Bobba, Montagu Hankin, Christopher Rovaldi, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 196.

https://doi.org/10.1182/blood-2023-180974

Published: 2023

Journal Articles

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Lynette C.Y. Chee, David M Ross, Shuh Ying Tan, Joel Wight, George Kannourakis, Miranda Ross, Wei Feng, Ying Jiang, Harveen Dhillon Natarajan, Christine Graham, Christopher Rovaldi, Simon Cooper, Jen L. Salstrom

Blood (2022) 140 (Supplement 1): 8181–8183.

https://doi.org/10.1182/blood-2022-166578

Published: 2022

Journal Articles

Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis

Claire Harrison, Shuh Ying Tan, David M Ross, George Kannourakis, Allie McGinty, Wei Feng, Ying Jiang, Christine Graham, Chris Rovaldi, Simon Cooper, Jen L. Salstrom

Blood (2022) 140 (Supplement 1): 9702–9703.

https://doi.org/10.1182/blood-2022-162761

Published: 2022

Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2021-147335

Published: 2021

Journal Articles

Evaluation the Value of TAT, PIC, tPAIC, TM in Diagnosing Disseminated Intravascular Coagulation in Chinese population: a Multi-Center Prospective Observational Study

Ying Jiang, MD, Heng Mei, PhDMD, Yu Hu, MD PhD

Blood (2017) 130 (Supplement 1): 3655.

https://doi.org/10.1182/blood.V130.Suppl_1.3655.3655

Published: 2017

Journal Articles

The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation

Roy F. Chemaly, Santosh S. Hanmod, Dhanesh B. Rathod, Shashank S. Ghantoji, Ying Jiang, Arpan Doshi, Karen Vigil, Javier A. Adachi, Andrew M. Khoury, Jeffery Tarrand, Chitra Hosing, Richard Champlin

Blood (2012) 119 (12): 2738–2745.

https://doi.org/10.1182/blood-2011-08-371112

Published: 2012

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

Novel Influenza A (2009/H1N1) Infection In Patients with Hematological Malignancies During the 2009 Pandemic Outbreak: Early Antiviral Treatment Improves Survival

Karen Joan Vigil, MD, Javier A Adachi, MD, Ying Jiang, MS, Uday Popat, MD, Mohsen Ghadimi Mahani, MD, Bruno P Granwehr, MD, Susan Gaeta, MD, Imrana Malik, MD, Richard Champlin, MD, Isaam I Raad, MD, Roy F Chemaly, MD, MPH

Blood (2010) 116 (21): 1731.

https://doi.org/10.1182/blood.V116.21.1731.1731

Published: 2010

Journal Articles

Lymphocyte Recovery Predicts Outcomes In Cord Blood and T-Cell Depleted Haploidentical Stem Cell Transplantation

Stefan O. Ciurea, MD, Victor E. Mulanovich, MD, Ying Jiang, PhD, Roland Bassett, Gabriela Rondon, MD, John McMannis, PhD, Marcos de Lima, MD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD

Blood (2010) 116 (21): 2316.

https://doi.org/10.1182/blood.V116.21.2316.2316

Published: 2010

Journal Articles

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

Ying Jiang, Andrew Dunbar, Lukasz P. Gondek, Sanjay Mohan, Manjot Rataul, Christine O'Keefe, Mikkael Sekeres, Yogen Saunthararajah, Jaroslaw P. Maciejewski

Blood (2009) 113 (6): 1315–1325.

https://doi.org/10.1182/blood-2008-06-163246

Published: 2009

NARROW

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

TBI/Ratg-Based Conditioning for Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in 11 Cases of Chemotherapy-Resistant Advanced-Stage Peripheral T-Cell Lymphoma

Real-World Effectiveness and Safety of Hetrombopag for Delayed Platelet Engraftment Post-Allogeneic Hematopoietic Stem Cell Transplantation

Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Impact of Immunosuppression Intensified Conditioning Regimen for Patients with Strong Positive Pre-Transplantation Donor Specific Anti-HLA Antibodies (DSAs) Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Evaluation the Value of TAT, PIC, tPAIC, TM in Diagnosing Disseminated Intravascular Coagulation in Chinese population: a Multi-Center Prospective Observational Study

The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Novel Influenza A (2009/H1N1) Infection In Patients with Hematological Malignancies During the 2009 Pandemic Outbreak: Early Antiviral Treatment Improves Survival

Lymphocyte Recovery Predicts Outcomes In Cord Blood and T-Cell Depleted Haploidentical Stem Cell Transplantation

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only